Reply To: NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs

Hematology Forums Hematology MCQ discussion forum NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs Reply To: NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs

#4176
thehematologist.orgthehematologist.org
Participant

35. Which of the following is not a factor bypass agent. Factor bypass agents are standard of care for bleeding hemophilia pateints with inhibitor ?

[1] FEIBA
[2] rFVII
[3] Emicizumab
[4] Idracizumab

Answer = [4] Idracizumab
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.